Cyberkinetics Neurotechnology Systems to Present at 5th Annual Biotech in Europe Investor Forum in Zurich, Switzerland.

FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN) today announced today that Timothy R. Surgenor, Cyberkinetics' President and Chief Executive Officer, will present at the 5th Annual Biotech in Europe Investor Forum on Wednesday, October 5th at 11:00 am. The conference, sponsored by Sachs Associates and Bloomberg LP, will feature 70 presentations by early to mid-stage biotech companies, as well as a series of panels, roundtable discussions and keynote presentations from leading investment, pharmaceutical and biotech companies. The conference will be attended by pharmaceutical and medical technology executives, as well as investors, fund managers and capital raising companies that are seeking deal-making opportunities.

E[acute accent]About Cyberkinetics Neurotechnology Systems, Inc.

E[acute accent]Cyberkinetics Neurotechnology Systems, a leader in brain interface technology, is developing products to treat nervous system diseases and disorders by bringing together advances in neuroscience, computer science and engineering. Cyberkinetics' products are based on over ten years of technology development and cutting-edge neuroscience research at leading academic institutions such as Brown University, the Massachusetts Institute of Technology, Emory University, and the University of Utah. E[acute accent]Cyberkinetics has received FDA clearance to market the NeuroPort(TM) System, a neural monitor designed for acute inpatient applications and labeled for temporary (less than 30 days) recording and monitoring of brain electrical activity. The NeuroPort(TM) System can contribute to the diagnosis and treatment of neurological conditions in patients who have undergone craniotomy by providing neurologists and neurosurgeons a new resource to detect, transmit and analyze neural activity. E[acute accent]Cyberkinetics' BrainGate(TM) System is being designed to give severely paralyzed individuals, as well as individuals with motor impairment from a variety of causes, a long-term, direct brain-computer interface for the purpose of communication and control of a computer, assistive devices, and, ultimately, limb movement. E[acute accent]More information is available at www.cyberkineticsinc.com. For specific information about BrainGate(TM) clinical trials please send an email to [e-mail].

E[acute accent]Forward Looking Safe Harbor Statement

E[acute accent]This announcement contains forward-looking statements, including statements about activities of Cyberkinetics' executive officers that may impact company performance and product development plans and progress. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.